Harmony Biosciences Holdings, Inc. has grown revenue 24% a year over three years and 32% a year over five, with earnings per share compounding at −1.9%. Revenue growth, 3-year annual rate: +24% (Biotechnology median +17%). Revenue growth, 5-year rate: +32%, growth has slowed since the five-year average. Earnings per share, 3-year rate: −1.9%, earnings lagged revenue: the growth is costing something. Years of annual history on file: 7, FY2019 to FY2025, as filed.

HRMYHarmony Biosciences Holdings, Inc.

Healthcare

$40.31+24% 1Y

$40.31

$25.9052 weeks$42.88

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +24% year on year, but operating margin narrowing (−5.2 points).

1 good, 1 to watch, 1 neutral

Revenue trend+24% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +32% a year.

Earnings trend−0% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction−5.2 points operating

Trailing-twelve-month operating margin, 23.7% now against 28.8% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is HRMY growing?

Harmony Biosciences Holdings, Inc. has grown revenue 24% a year over three years and 32% a year over five, with earnings per share compounding at −1.9%.

+24%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +32%
Revenue growth, 5-year rate · +24% over three · growth has slowed since the five-year average
Earnings per share, 3-year rate: −1.9%
Earnings per share, 3-year rate · revenue +24% · earnings lagged revenue: the growth is costing something
Years of annual history on file: 7
Years of annual history on file · FY2019 to FY2025, as filed